Hendrée E. Jones, Ph. D.

Associate Professor, Department of Psychiatry and Behavioral Sciences



Education

Randolph-Macon College, Ashland, VA, B.A. Honors, 1992, Psychology
University of Richmond, Richmond, VA, M.A., 1994, Psychology
Virginia Commonwealth University-Medical College of Virginia, Richmond, VA , Ph.D., 1997, Biopsychology

Employment

Johns Hopkins University, Baltimore, MD.

Associate Professor, Johns Hopkins University, Psychiatry Department, May 2004-present
Assistant Professor, Johns Hopkins University, Psychiatry Department, July 1999-May 2004
Director of Research for the Center for Addiction and Pregnancy, May 1998-present
Instructor, Johns Hopkins University, Psychiatry Department, May 1998- July 1999
Postdoctoral Research Fellow, Behavioral Pharmacology Research Unit, Department of Psychiatry, February 1997- April 1998.

Awards

1999 Young Psychopharmacologist Award of Division 28 of the American Psychological Association
1999 National Institute on Drug Abuse College on Problems of Drug Dependence Registration Award for Research on women and gender issues in the field of drug abuse
1999 College on Problems of Drug Dependence Travel Fellowship Award
Virginia Commonwealth University-Medical College of Virginia's Outstanding Biopsychology Student Award (1997)
American Psychological Association Dissertation Award (1997)
NIDA Director's Travel Award to attend the annual meeting of the Committee on Problems of Drug Dependence, San Juan Puerto Rico (1996)
Virginia Science Academy -Medical Sciences Section Graduate Student Competition Award (1996)
Outstanding Graduate Student Research, University of Richmond (1994)
Outstanding Graduate Student Research, University of Richmond (1993)
Graduate Research Travel Grant, University of Richmond (1993-1994)
Randolph-Macon College Department of Psychology Award for Academic Excellence (1992)

Licensure

Psychologist, State of Maryland, Lic. No. 3923

Other Professional Activities



Provided testimony at the oversight hearing entitled "Measuring the Effectiveness of Drug Addiction Treatment." March 30, 2004. Congressional Subcommittee on Criminal Justice, Drug Policy and Human Resources. Washington D.C.
NIAAA Small Business Innovation Research Contract Proposal. 2004-present. Grant Reviewer.
Friends Research Institute, Inc. Baltimore, Maryland. November 2003-Present. Institutional Review Board Member.
SAMHSA/CMHS/CSAT/CSAP, National Registry of Effective Treatment Programs. February 2003- present. Program Reviewer.
Johns Hopkins Bayview Medical Center, General Clinical Research Center Advisory Committee (IRB). Voting Member/Protocol reviewer. January 2003-present.
Center for Substance Abuse Treatment. Detoxification and Engagement in Substance Abuse Treatment, 2002. Consensus Panel Member for Treatment Improvement Protocol.
Ad-Hoc reviewer for Journal of Pharmacology and Experimental Therapeutics (1997-present)
Ad-Hoc reviewer for Drug and Alcohol Dependence (1997-present)
Ad-Hoc reviewer for Physiology and Behavior (1997-present)
American Psychological Association Graduate Student Campus Representative (1995-1997)
American Psychological Association Science Student Council (1996-present)

Publications

  1. Lambert KG, Kinsley CH, Jones HE, Klein SL, Pereitti SN & Stewart KM. (1995). Prenatal stress attenuates ulceration in the activity stress paradigm. Physiology and Behavior 57:989-994.
  2. Jones HE, Kunko P, Robinson SE & Balster R. (1996). Developmental consequences of intermittent and continuous prenatal exposure to 1,1,1-trichloroethane in mice. Pharmacology, Biochemistry and Behavior 55:635-646.
  3. Jones HE, Ruscio MA, Keyser LA, Gonzalez C, Billack B, Rowe R, Hancock C, Lambert KG & Kinsley, CH. (1997). Prenatal stress alters the size of the rostral anterior commissure in rats. Brain Research Bulletin 42:341-346.
  4. Jones HE & Balster RL (1997). Neurobehavioral consequences of intermittent prenatal exposure to high concentrations of toluene. Neurotoxicology and Teratology 19:305-313.
  5. Jones HE & Balster RL. (1997). Muscimol-like discriminative stimulus effects of GABA agonists in rats. Pharmacology, Biochemistry and Behavior 59:1-8.
  6. Jones HE, Li H & Balster RL. (1997). Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacology, Biochemistry and Behavior 58:1-6.
  7. Nicholson KL, Jones HE & Balster RL. (1997). Evaluation of the reinforcing and discriminative stimulus properties of the N-Methyl-D-Aspartate competitive antagonist NPC 17742 in rhesus monkeys.Behavioral Pharmacology 8:396-407.
  8. Jones HE, Strain EC, Bigelow GE, Walsh SL, Stitzer ML, Eissenberg T & Johnson RE. (1998). Induction with Levomethadyl acetate: Safety and Efficacy. Archives of General Psychiatry 55:729-736.
  9. Nicholson KL, Jones HE & Balster RL. (1998). Evaluation of the reinforcing and discriminative stimulus properties of the low affinity N-methyl-D-aspartate channel blocker memantine. Behavioral Pharmacology 9:231-243.
  10. Jones HE, Garrett BE & Griffiths RR. (1999). Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. Journal of Pharmacology and Experimental Therapeutics 288:188-197.
  11. Jones HE, Preston K & Bigelow GE. (1999). Discriminative and subjective effects of agonist-antagonist opioids in humans trained on a three-choice saline-hydromorphone low dose - hydromorphone high dose discrimination. Journal of Pharmacology and Experimental Therapeutics 289:1350-1361.
  12. Johnson RE, Jones HE & Jasinski DR. (1999). Human pharmacology and abuse liability of BW942C. Analgesia 4:19-26.
  13. Bowen SE, Wiley JL, Jones HE & Balster RL. (1999). Phencyclidine-and diazepam-like discriminative stimulus effects of abused inhalants in mice. Experimental Clinical Psychopharmacology 7:28-37.
  14. Jones HE, Herning RI & Griffiths RR. (2000). Effects of caffeine and caffeine withdrawal on cerebral blood velocities and electroencephalographic changes. Psychopharmacology 147:371-377.
  15. Jones HE, Haug NA, Stitzer ML, Svikis DS (2000). Improving treatment outcomes for pregnant drug-dependent women using low magnitude-voucher incentives. Addictive Behaviors, 25, 263-267.
  16. Jones HE, Herning RI, Griffiths RR (2000). Effects of caffeine and caffeine withdrawal on cerebral blood velocities and electroencephalographic changes. Psychopharmacology, 147, 371-377.
  17. Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ (2000). Nalmefene: Blockade of intravenous morphine challenge effects in opiate abusing humans. Drug and Alcohol Dependence, 60, 29-37.
  18. Haug NA, Jones HE, Moylan P, Eggleston M, Laban M, Svikis D (2000). Accuracy of the Nicometer in detecting cotinine levels. Nicotine & Tobacco Research, 2, 295.
  19. Jones HE, Haug N, Silverman K, Stitzer M, Svikis D (2001). The Effectiveness of incentives in enhancing treatment retention and drug abstinence in methadone-maintained pregnant women. Drug and Alcohol Dependence, 61, 297-306.
  20. Jones HE, Garrett BE, Griffiths RR (2001). Reinforcing effects of oral Cocaine: Contextual determinants. Psychopharmacology, 154, 143-152.
  21. Moylan PL, Jones HE, Haug NA, Kissin WB, Svikis DS (2001). Clinical and psychosocial characteristics of substance dependent pregnant women with and without PTSD. Addictive Behaviors, 26, 469-474.
  22. Johnson RE, Jones HE, Svikis DS, Haug N, Jansson L, Kissin WB, Alpan G, Lantz ME, Cone, EJ, Golden AS, Huggins GR, Lester B, Jasinski DR (2001). Buprenorphine induction and maintenance during pregnancy: An open-label study. Drug and Alcohol Dependence, 61, 97-103.
  23. Smith BJ, Jones HE, Griffiths RR (2001). Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology, 156, 435-444.
  24. Jansson L, Svikis DS, Velez M, Jones HE (2002). Impact of Managed Care on Treatment for Pregnant Drug-Dependent Women and their Children. Journal of Perinatology, 22, 5-6.
  25. Katz EC, Chutuape MA, Jones HE, Stitzer ML (2002). Voucher Reinforcement for Heroin and Cocaine Abstinence in an Outpatient Drug-free Program Experimental and Clinical Psychopharmacology, 10, 136-143.
  26. Jones HE, Svikis DS, Tran G. (2002). Relationship between patient compliance and maternal and infant outcomes in pregnant drug misusing women. Substance Use and Misuse, 37, 1411-1422.
  27. Perry, B, Jones H, Tuten M, Svikis D (2003). Assessing Maternal Perceptions of Harmful Effects of Drug Use During Pregnancy. Journal of Addictive Diseases, 22, 1-9.
  28. Jones HE, Griffiths RR. (2003). Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. Psychopharmacology, 165, 280-290.
  29. Tuten M, Jones HE, Svikis DS. (2003). Comparing Homeless and Domiciled Pregnant Substance Dependent Women on Psychosocial Characteristics and Treatment Outcomes. Drug and Alcohol Dependence, 69, 95-99.
  30. Tuten M, Jones HE. (2003). A Partner’s drug using status impacts women’s drug treatment outcome. Drug and Alcohol Dependence, 70, 327-330.
  31. Johnson RE, Jones HE, Fischer G. (2003). Use of Buprenorphine in Pregnancy: Patient Management and Effects on the Neonate. Drug Alcohol Dependence, 70, S87-S101.
  32. Jones H, Svikis D, Rosado J, Tuten M, Kulstad J. (In press). What If They Do Not Want Treatment?: Lessons Learned from Intervention Studies Of Non-Treatment Seeking Drug Using Pregnant Women. American Journal on Addictions.
  33. Cumberbatch Z, Copersino M, Stitzer M, Jones H. (In press). Comparative drug use and psychosocial profiles of opioid dependents applying for methadone versus drug-free treatment. American Journal of Drug and Alcohol Abuse.
  34. Tuten M, Jones HE, Tuten M, Tran G, Svikis D. (In press). Partner Violence Impacts the Psychosocial and Psychiatric Status of Pregnant Drug Dependent Women. Addictive Behaviors.
  35. Jones HE, Johnson RE, Bigelow GE, Strain EC. (In press). Differences at Treatment Entry Between Opioid-Dependent and Cocaine-Dependent Males and Females. Addictive Disorders and Their Treatment.
  36. Jones HE, Johnson RE, Ahmed MS, Fischer G, Finnegan LP. (2004). How Far Have We Come Baby?: The Current Knowledge About Exposure to Buprenorphine During Pregnancy and Lactation. NIDA Research Monograph 184. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
  37. Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. (In press). Neonatal abstinence syndrome in methadone exposed infants is altered by level of prenatal tobacco exposure. Drug and Alcohol Dependence.
  38. Jones HE, Johnson R.E, Bigelow G.E, Silverman K, Mudric T, Strain, E.C. (In press). Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial. American Journal on Addictions.
  39. Jones, HE. (In press). Practical Considerations for the Clinical Use of Buprenorphine. Science & Practice Perspectives (a National Institute on Drug Abuse peer-reviewed publication).
Chapters
  1. Kinsley CH, Lambert KG & Jones HE. (1996). Chapter 5-Prenatal stress-induced modifications of sexual differentiation. In Lee Ellis (ed). Sexual Orientation and Sex Differences in Behavior. New York: Praeger, pp. 200-245.
  2. Jones HE & Balster RL. (1998). Inhalant abuse in pregnancy. In: JR. Woods ed. Obstetrics and Gynecology Clinics of North America. Philadelphia: W.B. Saunders Co. PP. 8-1 - 8-15.
  3. Jones HE, Velez ML, McCaul ME & Svikis DS. (1999). Chapter 12- Special treatment issues for women. In: EC Strain & M Stitzer eds. Methadone Treatment for Opioid Dependence. Baltimore: Johns Hopkins University Press. pp. 251-280.
  4. Wong, CJ, Jones, HE, Stitzer ML. (2003). Chapter 22 Contingency Management Interventions for the Treatment of Substance Abuse: Abstinence Reinforcement Procedures and the Community Reinforcement Approach Behavior Therapy. In: Cox M and Klinger E (eds). Handbook of Motivational Counseling. New York, NY: Wiley, Inc. pp421-438.

E-mail contact: hejones@jhmi.edu Updated: 6/1/2004
http://bpru.med.jhu.edu/bio/jones.html